1. Home
  2. PVLA vs KOPN Comparison

PVLA vs KOPN Comparison

Compare PVLA & KOPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PVLA
  • KOPN
  • Stock Information
  • Founded
  • PVLA 2015
  • KOPN 1984
  • Country
  • PVLA United States
  • KOPN United States
  • Employees
  • PVLA N/A
  • KOPN N/A
  • Industry
  • PVLA Biotechnology: Pharmaceutical Preparations
  • KOPN Semiconductors
  • Sector
  • PVLA Health Care
  • KOPN Technology
  • Exchange
  • PVLA Nasdaq
  • KOPN Nasdaq
  • Market Cap
  • PVLA 285.2M
  • KOPN 255.1M
  • IPO Year
  • PVLA N/A
  • KOPN 1992
  • Fundamental
  • Price
  • PVLA $53.42
  • KOPN $1.89
  • Analyst Decision
  • PVLA Strong Buy
  • KOPN Strong Buy
  • Analyst Count
  • PVLA 11
  • KOPN 2
  • Target Price
  • PVLA $56.64
  • KOPN $2.63
  • AVG Volume (30 Days)
  • PVLA 153.4K
  • KOPN 2.5M
  • Earning Date
  • PVLA 08-14-2025
  • KOPN 08-12-2025
  • Dividend Yield
  • PVLA N/A
  • KOPN N/A
  • EPS Growth
  • PVLA N/A
  • KOPN N/A
  • EPS
  • PVLA N/A
  • KOPN N/A
  • Revenue
  • PVLA N/A
  • KOPN $46,959,478.00
  • Revenue This Year
  • PVLA N/A
  • KOPN $8.02
  • Revenue Next Year
  • PVLA N/A
  • KOPN $20.99
  • P/E Ratio
  • PVLA N/A
  • KOPN N/A
  • Revenue Growth
  • PVLA N/A
  • KOPN 13.03
  • 52 Week Low
  • PVLA $11.17
  • KOPN $0.56
  • 52 Week High
  • PVLA $53.93
  • KOPN $2.50
  • Technical
  • Relative Strength Index (RSI)
  • PVLA 85.86
  • KOPN 51.83
  • Support Level
  • PVLA $46.08
  • KOPN $1.68
  • Resistance Level
  • PVLA $50.22
  • KOPN $2.04
  • Average True Range (ATR)
  • PVLA 3.11
  • KOPN 0.17
  • MACD
  • PVLA 0.70
  • KOPN -0.02
  • Stochastic Oscillator
  • PVLA 97.00
  • KOPN 38.18

About PVLA Palvella Therapeutics Inc. Common Stock

Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.

About KOPN Kopin Corporation

Kopin Corp is a provider of high-performance application-specific optical solutions consisting of high-resolution microdisplays and optics, subassemblies, and headsets. It serves soldiers, avionics, armored vehicles training and simulation military applications, and others. Its product portfolio includes Microdisplays, Spatial Light Modulators, Optical Modules, Medical, Training, and Simulation. Geographically, it derives a majority of its revenue from the Americas and also has a presence in Asia-Pacific; Europe, and Other Countries.

Share on Social Networks: